| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 08/24/2005 | CN1215768C Active ingredient compositions having insecticidal and acaricidal properties |
| 08/23/2005 | US6934639 Using the three-dimensional structure of human collagenase-3 (MMP-13), a member of the matrix metalloproteinase (MMP) for drug design of MMP-13 inhibitors |
| 08/23/2005 | US6933422 Nav2 channel gene-deficient mice |
| 08/23/2005 | US6933387 Anti-obesity 1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indoles |
| 08/23/2005 | US6933386 Process for preparing certain pyrrolotriazine compounds |
| 08/23/2005 | US6933321 For therapy of androgen-dependent diseases such as prostate cancer, benign prostatic hyperplasia, precicious puberty, polycystic ovarian syndrome, acne, hirsutism, seborrhea, androgenic alopecia and premature male baldness |
| 08/23/2005 | US6933320 Combination comprising combretastatin and anticancer agents |
| 08/23/2005 | US6933315 bis indole derivatives containing acetylated saccharide groups |
| 08/23/2005 | US6933303 Antidiabetic agents |
| 08/23/2005 | US6933301 1,2,3,6-tetrahydropyrimidine-2-one compositions, articles and therapeutic methods for upper airway breathing disorders |
| 08/23/2005 | US6933286 Therapeutic delivery compositions and methods of use thereof |
| 08/23/2005 | US6933285 Flavin N-oxides: new anti-cancer agents and pathogen eradication agents |
| 08/23/2005 | US6933278 Administering as hypotensive agents, somatotrophins and optionally angiotensin 1-converting enzyme inhibitors, to humans having congenital disorders |
| 08/23/2005 | US6933147 Human cyclic nucleotide-gated channel polypeptide |
| 08/23/2005 | US6933142 Mammalian glycosylsulfotransferases expressed in high endothelial cells (HEC-GLCNAC6ST) and polypeptides coded by nucleic acids, used for medical diagnosis, drug screening and therapy |
| 08/23/2005 | US6933129 Method for culturing and assaying cells |
| 08/23/2005 | CA2469592C Hiv integrase inhibitors |
| 08/23/2005 | CA2265668C Methylphenidate tablet |
| 08/23/2005 | CA2265116C Structured water in cosmetic compositions |
| 08/23/2005 | CA2223469C Use of dopamine receptor antagonists in palliative tumour therapy |
| 08/23/2005 | CA2094276C Antibodies against the urokinase receptor and their use |
| 08/18/2005 | WO2005075484A2 Chemokine ccr5 receptor modulators |
| 08/18/2005 | WO2005075414A1 Peptidyl arginine deiminase type iv inhibitor |
| 08/18/2005 | WO2005075022A2 Susceptibility gene for myocardial infraction, stroke, and paod; methods of treatment |
| 08/18/2005 | WO2005074995A2 Combined use of prame inhibitors and hdac inhibitors |
| 08/18/2005 | WO2005074990A2 Methods of preventing and treating sars using low ph respiratory tract compositions |
| 08/18/2005 | WO2005074989A2 Combination of a dna topoisomerase inhibitor and an iap inhibitor |
| 08/18/2005 | WO2005074988A1 Nerve cell differentiation inducer |
| 08/18/2005 | WO2005074983A2 Treatment of rhinitis with anticholinergics alone in combination with antihistamines phosphodiesterase 4 inhibitors, or corticosteroids |
| 08/18/2005 | WO2005074982A2 Combination of anticholinergics and inhibitors of phosphodiesterase type 4 for the treatment of respiratory diseases |
| 08/18/2005 | WO2005074947A2 Anti-viral pharmaceutical compositions |
| 08/18/2005 | WO2005074925A1 Compositions substantially free of galactomannan containing piperacillin and tazobactam |
| 08/18/2005 | WO2005074923A1 Methods and compositions |
| 08/18/2005 | WO2005074918A1 The combination of anticholinergics and glucocorticoids for the long-term treatment of asthma and copd |
| 08/18/2005 | WO2005074909A1 Combination drug |
| 08/18/2005 | WO2005074908A1 Use of aminosalicylates in diarrhoea-predominent irritable bowel syndrome |
| 08/18/2005 | WO2005074900A2 NOVEL COMBINATION OF ANTICHOLINERGIC AND β MIMETICS FOR THE TREATMENT OF RESPIRATORY DISEASES |
| 08/18/2005 | WO2005074898A2 Composition comprising (s) pantoprazole and an antibiotic for treating helicobacter pylori |
| 08/18/2005 | WO2005074896A1 Sustained release preparation |
| 08/18/2005 | WO2005074460A2 Methods of enhancing immune response in the intradermal compartment and compounds useful in the methods |
| 08/18/2005 | WO2005053613A3 Combinations for the treatment of fungal infections |
| 08/18/2005 | WO2005042048A3 Bioactive hydrogel compositions for regenerating connective tissue |
| 08/18/2005 | WO2005039485A3 Gsk-3 inhibitors and uses thereof |
| 08/18/2005 | WO2005027841A3 Cells, compositions and methods for repressing b cell autoantibody secretion and for treating autoimmune disease |
| 08/18/2005 | WO2005026318A3 Methods and compositions for producing antigenic responses |
| 08/18/2005 | WO2004075857A3 Compositions, combinations, and methods for treating cardiovascular conditions and other associated conditions |
| 08/18/2005 | WO2003004608A3 Drug metabolizing enzymes |
| 08/18/2005 | WO2002099049A3 Tbc1d1s as modifiers of the p53 pathway and methods of use |
| 08/18/2005 | US20050183146 Inhibitors of the inositol polyphosphate 5-phosphatase SHIP2 molecule |
| 08/18/2005 | US20050182418 Devices and methods for the restoration of a spinal disc |
| 08/18/2005 | US20050182256 1-{1-[4-(6-hydroxy-5-isobutyl-3-phenylpyrazin-2-yl)benzyl]piperidin-4-yl}-1,3-dihydro-2H-benzimidazol-2-one; antiproliferative |
| 08/18/2005 | US20050182244 Modified polypeptides stabilized in a desired conformation and methods for producing same |
| 08/18/2005 | US20050182236 Star polymer such as of a polylactone based on a central phosphorus atom derived from phosphorus oxychloride (POCl3) or ethyl dichlorophosphate; biodegradable and/or biocompatible; sustained release drug delivery; reverse thermal gelation |
| 08/18/2005 | US20050182136 Side effect reduction |
| 08/18/2005 | US20050182106 Medicinal composition for mitigating blood lipid or lowering blood homocysteine |
| 08/18/2005 | US20050182105 Method of using 3-cyano-4-arylpyridine derivatives as modulators of androgen receptor function |
| 08/18/2005 | US20050182103 Substituted 2,3-diphenyl pyridines |
| 08/18/2005 | US20050182077 8-amino-7-substituted-2,6-dioxo-1,2,3,6-tetrahydro-7H-purines; erectile dysfunction; sexual disorders; psychological disorders; hypotensive agents; restenosis; cardiovascular disorders; antidiabetic agents; vision defects; autoimmune diseases; anticancer agents |
| 08/18/2005 | US20050182076 Transdermal penetration system and treatment for cellulite |
| 08/18/2005 | US20050182075 For prophylaxis and therapy of hemorrhagic virus infection, autoimmune diseases, autograft rejection, neoplasm, hyperhomocysteineuria, cardiovascular disease, stroke, Alzheimer's disease, or diabetes; can be used in combination with an anti-hemorrhagic viral infection agent, an immunosuppressant |
| 08/18/2005 | US20050182074 fluconazole as cytochrome P-450 isoenzyme CYP2C17 inhibitor; dosage form; separate containers containing fluconazole and voriconazole |
| 08/18/2005 | US20050182049 Combination of gamma-aminobutyric acid modulators and 5-HT1B receptor antagonists |
| 08/18/2005 | US20050182047 Treatment of demyelinating disorders |
| 08/18/2005 | US20050182045 Fused ring 4-oxopyrimidine derivative |
| 08/18/2005 | US20050182042 Pharmaceutical composition comprising a renin inhibitor, a calcium channel blocker and a diuretic |
| 08/18/2005 | US20050182036 Medicinal composition containing an HMG-CoA reductase inhibitor |
| 08/18/2005 | US20050182028 bisphosphonates ( alendronate sodium) as anionic substances could potentially be carried by a cation-bearing aminoalkyl methacrylate copolymer a cation-bearing polymer resulting in a conjugate with a better in vivo absorption |
| 08/18/2005 | US20050182017 Immunostimulatory nucleic acid molecules |
| 08/18/2005 | US20050182003 Drugs to be used in gene therapy for recessively transmitted genetic disease |
| 08/18/2005 | US20050181996 Stimulation of cartilage growth with agonists of the non-proteolytically activated thrombin receptor |
| 08/18/2005 | US20050181991 Use of artemin, a member of the GDNF ligand family |
| 08/18/2005 | US20050181980 Administering a formulation comprising an effective amount of:a sulfonylurea receptor 1 (SUR1) antagonist that reduces the activity of a NCCa-ATP channel; a pharmaceutically acceptable carrier |
| 08/18/2005 | US20050181971 Treatment of type i diabetes mellitus |
| 08/18/2005 | US20050181501 Anti-TECK antibodies and methods of use therefor |
| 08/18/2005 | US20050181462 Mutant androgen receptor, cancer cells expressing the same, a method of producing them and use thereof |
| 08/18/2005 | US20050181457 Mixture comprising immunogllobulin G complex for diagnosis, prevention and treatment of autoimmune and allergic disorders |
| 08/18/2005 | US20050181422 Process for high throughput screening of CpG-based immuno-agonist/antagonist |
| 08/18/2005 | US20050181415 Drug metabolizing enzymes |
| 08/18/2005 | US20050181414 Peptides associated with serine protease active site for use in identification of modulators for treatment of cell proliferative disorders |
| 08/18/2005 | US20050181391 Method of detecting and treating tuberous sclerosis complex associated disorders |
| 08/18/2005 | US20050181368 Protein for use in hypoxia related conditions |
| 08/18/2005 | US20050181072 Use of essential oils for combating gi tract infection by helicobacter-like organisms |
| 08/18/2005 | US20050181071 Reducing neurotransmission in the limbic system of the human brain as a means of treating depressive symptoms |
| 08/18/2005 | US20050181070 Compositions of an anticonvulsant and an antipsychotic drug and methods of using the same for affecting weight loss |
| 08/18/2005 | US20050181066 Novel use of guanylate cyclase activators for the treatment of respiratory insufficiency |
| 08/18/2005 | US20050181063 Biologically active agent being encapsulated within microspheres which comprise a polymer which has a molecular weight in excess of 94 kDa and a maximum diameter of 20 mu m; for the intra-nasal administration of vaccines in a single shot vaccination |
| 08/18/2005 | US20050181054 comprising a water-insoluble and/or water-low soluble substance, a medicament, and an aqueous medium, and having an osmotic pressure of less than 290 mOsm; efficient penetration and high permeability blood at the mucosa |
| 08/18/2005 | US20050181053 Comprises methacrylic acid-methyl methacrylate copolymer layers for drug delivery to gastrointestinal tract ; solid unit dosage form for oral administration; improved resistance to coating fractures |
| 08/18/2005 | US20050181046 Tamper-resistant oral opioid agonist formulations |
| 08/18/2005 | US20050181028 Topical composition and method for treating occlusive wounds |
| 08/18/2005 | US20050181022 Confectionary products including agent for controlling weight |
| 08/18/2005 | US20050181018 Ocular drug delivery |
| 08/18/2005 | US20050180993 Assays for the identification of compounds that inhibit assembly of nucleoprotein (NP), virion-associated proteins VP35, and VP24, or inhibit the glycosylation of NP, required for nucleocapsid formation, for use as anti-viral agents |
| 08/18/2005 | US20050180982 Assessing metastatic potential of carcinoma cells by contacting cells in tissue sample suspected of containing carcinoma with detectable indicator capable of binding to cad-11 or cad-11 mRNA and determining presence or absence of cad-11 expression in tissue; method of preventing or terminating pregnancy |
| 08/18/2005 | US20050180981 Human checkpoint kinase, hCDS1, compositions and methods |
| 08/18/2005 | US20050180975 Combined use of anti-cytokine antibodies or antagonists and anti-CD20 for treatment of B cell lymphoma |
| 08/18/2005 | US20050180973 TREM-1 splice variant for use in modifying immune responses |
| 08/18/2005 | US20050180971 Cancer therapy |
| 08/18/2005 | US20050180962 treating a non-alcoholic fatty liver disease; inactivated probiotic bacteria; and a pharmaceutically acceptable excipient; gastrointestinal inflammation; allergic asthma |
| 08/18/2005 | US20050180959 Kinases involved in the regulation of energy homeostasis |